Scarica l'app Stockscreener
82.21
0.91%
0.74
Dopo l'orario di chiusura:
82.47
0.26
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NFLX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$81.47
Aprire:
$82.715
Volume 24 ore:
43.26M
Relative Volume:
0.96
Capitalizzazione di mercato:
$347.10B
Reddito:
$45.27B
Utile/perdita netta:
$10.98B
Rapporto P/E:
32.53
EPS:
2.5272
Flusso di cassa netto:
$9.46B
1 W Prestazione:
+2.84%
1M Prestazione:
-8.10%
6M Prestazione:
-32.15%
1 anno Prestazione:
-20.00%
Intervallo 1D:
$82.09
$84.66
Intervallo di 1 settimana:
$79.22
$84.66
Portata 52W:
$79.22
$134.12
Netflix Inc Stock (NFLX) Company Profile
Nome
Netflix Inc
Settore
Industria
Telefono
408-540-3700
Indirizzo
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FOXA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NFLX
Netflix Inc
|
82.21 | 343.98B | 45.27B | 10.98B | 9.46B | 2.5272 |
|
DIS
Walt Disney Co
|
109.96 | 189.78B | 95.62B | 13.27B | 7.06B | 6.7872 |
|
WBD
Warner Bros Discovery Inc
|
27.80 | 67.47B | 37.87B | 356.00M | 4.13B | 0.1876 |
|
LYV
Live Nation Entertainment Inc
|
149.32 | 34.35B | 24.57B | 532.09M | 1.59B | 1.37 |
|
FOXA
Fox Corporation
|
63.37 | 26.74B | 16.47B | 2.07B | 2.67B | 4.4433 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Reiterato | Robert W. Baird | Outperform |
| 2026-01-21 | Reiterato | BMO Capital Markets | Outperform |
| 2026-01-21 | Reiterato | Canaccord Genuity | Buy |
| 2026-01-21 | Reiterato | Deutsche Bank | Hold |
| 2026-01-21 | Reiterato | Goldman | Neutral |
| 2026-01-21 | Reiterato | Guggenheim | Buy |
| 2026-01-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Reiterato | Morgan Stanley | Overweight |
| 2026-01-21 | Reiterato | Needham | Buy |
| 2026-01-21 | Reiterato | Oppenheimer | Outperform |
| 2026-01-21 | Reiterato | Piper Sandler | Overweight |
| 2026-01-21 | Reiterato | Pivotal Research Group | Hold |
| 2026-01-21 | Reiterato | Rosenblatt | Neutral |
| 2026-01-21 | Reiterato | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Reiterato | TD Cowen | Buy |
| 2026-01-21 | Reiterato | UBS | Buy |
| 2026-01-21 | Reiterato | Wolfe Research | Outperform |
| 2026-01-12 | Iniziato | HSBC Securities | Buy |
| 2026-01-09 | Reiterato | Goldman | Neutral |
| 2025-12-08 | Downgrade | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Downgrade | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Reiterato | Barclays | Equal Weight |
| 2025-10-31 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-07 | Aggiornamento | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Aggiornamento | Loop Capital | Hold → Buy |
| 2025-07-10 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Downgrade | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Reiterato | Canaccord Genuity | Buy |
| 2025-07-02 | Reiterato | Goldman | Neutral |
| 2025-06-20 | Reiterato | Pivotal Research Group | Buy |
| 2025-06-12 | Reiterato | Oppenheimer | Outperform |
| 2025-06-03 | Reiterato | Jefferies | Buy |
| 2025-05-30 | Reiterato | BofA Securities | Buy |
| 2025-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Reiterato | BMO Capital Markets | Outperform |
| 2025-04-21 | Reiterato | Barclays | Equal Weight |
| 2025-04-21 | Reiterato | Canaccord Genuity | Buy |
| 2025-04-21 | Reiterato | Guggenheim | Buy |
| 2025-04-21 | Reiterato | JP Morgan | Overweight |
| 2025-04-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Reiterato | MoffettNathanson | Buy |
| 2025-04-21 | Reiterato | Morgan Stanley | Overweight |
| 2025-04-21 | Reiterato | Oppenheimer | Outperform |
| 2025-04-21 | Reiterato | Piper Sandler | Overweight |
| 2025-04-21 | Reiterato | Pivotal Research Group | Buy |
| 2025-04-21 | Reiterato | Wells Fargo | Overweight |
| 2025-04-17 | Ripresa | Piper Sandler | Overweight |
| 2025-03-27 | Iniziato | FBN Securities | Outperform |
| 2025-03-17 | Aggiornamento | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Reiterato | Oppenheimer | Outperform |
| 2025-01-22 | Reiterato | Pivotal Research Group | Buy |
| 2025-01-22 | Aggiornamento | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Aggiornamento | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Aggiornamento | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Reiterato | BMO Capital Markets | Outperform |
| 2025-01-15 | Reiterato | Oppenheimer | Outperform |
| 2025-01-08 | Reiterato | Goldman | Neutral |
| 2025-01-06 | Reiterato | Argus | Buy |
| 2025-01-03 | Reiterato | The Benchmark Company | Sell |
| 2024-12-19 | Reiterato | UBS | Buy |
| 2024-12-16 | Downgrade | Loop Capital | Buy → Hold |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-11 | Reiterato | JP Morgan | Overweight |
| 2024-11-20 | Reiterato | Pivotal Research Group | Buy |
| 2024-10-18 | Reiterato | Needham | Buy |
| 2024-10-18 | Reiterato | Oppenheimer | Outperform |
| 2024-10-18 | Reiterato | Pivotal Research Group | Buy |
| 2024-10-16 | Reiterato | Loop Capital | Buy |
| 2024-10-11 | Reiterato | Guggenheim | Buy |
| 2024-10-10 | Reiterato | Morgan Stanley | Overweight |
| 2024-10-10 | Reiterato | Oppenheimer | Outperform |
| 2024-10-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Iniziato | China Renaissance | Hold |
| 2024-08-30 | Reiterato | Pivotal Research Group | Buy |
| 2024-07-17 | Reiterato | Guggenheim | Buy |
| 2024-07-16 | Reiterato | The Benchmark Company | Sell |
| 2024-07-15 | Reiterato | BofA Securities | Buy |
| 2024-07-12 | Reiterato | JP Morgan | Overweight |
| 2024-07-10 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Reiterato | TD Cowen | Buy |
| 2024-07-02 | Reiterato | Argus | Buy |
| 2024-05-28 | Reiterato | Evercore ISI | Outperform |
| 2024-04-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Aggiornamento | Needham | Hold → Buy |
| 2024-04-19 | Reiterato | Pivotal Research Group | Buy |
| 2024-04-15 | Reiterato | Deutsche Bank | Hold |
| 2024-04-12 | Reiterato | Morgan Stanley | Overweight |
| 2024-04-12 | Reiterato | Piper Sandler | Neutral |
| 2024-04-05 | Reiterato | Pivotal Research Group | Buy |
| 2024-03-25 | Reiterato | Citigroup | Neutral |
| 2024-03-12 | Reiterato | Jefferies | Buy |
| 2024-03-11 | Reiterato | Oppenheimer | Outperform |
| 2024-01-30 | Downgrade | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Aggiornamento | DZ Bank | Hold → Buy |
| 2024-01-24 | Reiterato | BMO Capital Markets | Outperform |
| 2024-01-24 | Reiterato | BofA Securities | Buy |
| 2024-01-24 | Reiterato | Canaccord Genuity | Buy |
| 2024-01-24 | Reiterato | Evercore ISI | Outperform |
| 2024-01-24 | Reiterato | Goldman | Neutral |
| 2024-01-24 | Reiterato | Guggenheim | Buy |
| 2024-01-24 | Reiterato | JP Morgan | Overweight |
| 2024-01-24 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2024-01-24 | Reiterato | Morgan Stanley | Overweight |
| 2024-01-24 | Reiterato | Oppenheimer | Outperform |
| 2024-01-24 | Reiterato | Piper Sandler | Neutral |
| 2024-01-24 | Reiterato | Pivotal Research Group | Buy |
| 2024-01-24 | Reiterato | Redburn Atlantic | Buy |
| 2024-01-24 | Reiterato | Robert W. Baird | Outperform |
| 2024-01-24 | Reiterato | TD Cowen | Outperform |
| 2024-01-24 | Reiterato | UBS | Buy |
| 2024-01-24 | Reiterato | Wells Fargo | Overweight |
| 2023-09-18 | Reiterato | Evercore ISI | Outperform |
| 2023-08-25 | Aggiornamento | Loop Capital | Hold → Buy |
| 2023-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Reiterato | Deutsche Bank | Buy |
| 2023-07-13 | Reiterato | JP Morgan | Overweight |
| 2023-07-12 | Reiterato | UBS | Buy |
| 2023-07-05 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-29 | Reiterato | Citigroup | Buy |
| 2023-06-28 | Reiterato | Oppenheimer | Outperform |
| 2023-06-13 | Reiterato | BofA Securities | Buy |
| 2023-06-13 | Reiterato | Guggenheim | Buy |
| 2023-04-19 | Reiterato | Deutsche Bank | Buy |
| 2023-04-19 | Reiterato | JP Morgan | Overweight |
| 2023-04-19 | Reiterato | Jefferies | Buy |
| 2023-04-19 | Reiterato | Piper Sandler | Neutral |
| 2023-04-19 | Reiterato | Pivotal Research Group | Buy |
| 2023-04-19 | Reiterato | Rosenblatt | Neutral |
| 2023-04-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-11 | Ripresa | Robert W. Baird | Neutral |
| 2023-01-23 | Reiterato | Argus | Buy |
| 2023-01-20 | Reiterato | Canaccord Genuity | Buy |
| 2023-01-20 | Reiterato | Deutsche Bank | Buy |
| 2023-01-20 | Reiterato | Evercore ISI | Outperform |
| 2023-01-20 | Reiterato | Goldman | Sell |
| 2023-01-20 | Reiterato | Guggenheim | Buy |
| 2023-01-20 | Reiterato | Jefferies | Buy |
| 2023-01-20 | Reiterato | MoffettNathanson | Market Perform |
| 2023-01-20 | Reiterato | Oppenheimer | Outperform |
| 2023-01-20 | Reiterato | Piper Sandler | Neutral |
| 2023-01-20 | Reiterato | Pivotal Research Group | Buy |
| 2023-01-20 | Reiterato | Robert W. Baird | Neutral |
| 2023-01-20 | Reiterato | The Benchmark Company | Sell |
| 2023-01-20 | Reiterato | Wedbush | Outperform |
| 2023-01-20 | Reiterato | Wolfe Research | Outperform |
| 2023-01-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-04 | Iniziato | New Street | Neutral |
| 2022-12-29 | Aggiornamento | CFRA | Sell → Buy |
| 2022-12-14 | Reiterato | Jefferies | Hold |
| 2022-12-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Downgrade | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Downgrade | Goldman | Neutral → Sell |
| 2022-05-16 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-04-21 | Downgrade | DZ Bank | Buy → Hold |
| 2022-04-21 | Downgrade | Edward Jones | Buy → Hold |
| 2022-04-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Aggiornamento | Needham | Underperform → Hold |
| 2022-04-20 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Downgrade | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Downgrade | Stifel | Buy → Hold |
| 2022-04-20 | Downgrade | UBS | Buy → Neutral |
| 2022-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Iniziato | Rosenblatt | Neutral |
| 2022-03-09 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Edward Jones | Hold → Buy |
| 2022-01-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-21 | Reiterato | BMO Capital Markets | Outperform |
| 2022-01-21 | Reiterato | BofA Securities | Buy |
| 2022-01-21 | Reiterato | Canaccord Genuity | Buy |
| 2022-01-21 | Reiterato | Cowen | Outperform |
| 2022-01-21 | Reiterato | Deutsche Bank | Hold |
| 2022-01-21 | Reiterato | Goldman | Neutral |
| 2022-01-21 | Reiterato | Guggenheim | Buy |
| 2022-01-21 | Reiterato | JP Morgan | Overweight |
| 2022-01-21 | Reiterato | MoffettNathanson | Neutral |
| 2022-01-21 | Downgrade | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Reiterato | Oppenheimer | Outperform |
| 2022-01-21 | Reiterato | Piper Sandler | Overweight |
| 2022-01-21 | Reiterato | Pivotal Research Group | Buy |
| 2022-01-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Reiterato | Stifel | Buy |
| 2022-01-21 | Aggiornamento | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Downgrade | Truist | Buy → Hold |
| 2022-01-21 | Reiterato | UBS | Buy |
| 2022-01-21 | Reiterato | Wolfe Research | Outperform |
| 2021-12-15 | Reiterato | The Benchmark Company | Sell |
| 2021-10-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Reiterato | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Reiterato | The Benchmark Company | Sell |
| 2021-09-13 | Iniziato | Goldman | Neutral |
| 2021-09-08 | Reiterato | JP Morgan | Overweight |
| 2021-09-07 | Reiterato | Atlantic Equities | Overweight |
| 2021-07-21 | Reiterato | Credit Suisse | Outperform |
| 2021-07-21 | Reiterato | Deutsche Bank | Buy |
| 2021-07-21 | Reiterato | JP Morgan | Overweight |
| 2021-07-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Reiterato | Stifel | Buy |
| 2021-06-25 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Iniziato | Edward Jones | Hold |
| 2021-05-19 | Ripresa | Jefferies | Buy |
| 2021-04-21 | Ripresa | Oppenheimer | Outperform |
| 2021-04-21 | Reiterato | Pivotal Research Group | Buy |
| 2021-04-21 | Aggiornamento | Stifel | Hold → Buy |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-04-01 | Iniziato | Piper Sandler | Overweight |
| 2021-03-25 | Reiterato | The Benchmark Company | Sell |
| 2021-03-23 | Aggiornamento | Argus | Hold → Buy |
| 2021-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-01-20 | Reiterato | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Reiterato | Pivotal Research Group | Buy |
| 2021-01-20 | Reiterato | The Benchmark Company | Sell |
| 2021-01-20 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Reiterato | BMO Capital Markets | Outperform |
| 2020-10-21 | Reiterato | Bernstein | Outperform |
| 2020-10-21 | Reiterato | Jefferies | Buy |
| 2020-10-21 | Reiterato | Morgan Stanley | Overweight |
| 2020-10-21 | Reiterato | Oppenheimer | Outperform |
| 2020-10-21 | Reiterato | Piper Sandler | Overweight |
| 2020-10-21 | Reiterato | Pivotal Research Group | Buy |
| 2020-10-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-10-21 | Reiterato | The Benchmark Company | Sell |
| 2020-10-21 | Reiterato | Wedbush | Underperform |
| 2020-10-21 | Reiterato | Wells Fargo | Equal Weight |
| 2020-10-16 | Reiterato | Morgan Stanley | Overweight |
| 2020-10-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-10-14 | Reiterato | Goldman | Buy |
| 2020-10-07 | Reiterato | Pivotal Research Group | Buy |
| 2020-09-28 | Reiterato | The Benchmark Company | Sell |
| 2020-09-15 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Ripresa | Raymond James | Mkt Perform |
| 2020-09-04 | Reiterato | The Benchmark Company | Sell |
| 2020-07-29 | Reiterato | Loop Capital | Buy |
Mostra tutto
Netflix Inc Borsa (NFLX) Ultime notizie
Is Netflix Stock Your Ticket to Becoming a Millionaire? - AOL.com
Shin Hye-sun and Na In-woo are reuniting for a new Netflix romantic comedy series, "Love O’Clock," which is set to put a chaotic twist on the body-swap trope. Read the story in the link in the comments section. - facebook.com
Paramount Skydance Sweetens Warner Bros. Bid with Netflix Fee Cover, Stock Surges - TipRanks
Paramount Skydance Bid Puts Netflix Warner Bros Deal And Valuation In Focus - Yahoo Finance
Activist investor takes aim at Warner Bros deal with Netflix - Financial Times
Warner Bros-Netflix Deal: Activist Reportedly Builds $200M Stake In WBD, Nudges It To Review Paramount’s Bid Thoroughly - Stocktwits
Activist investor Ancora pushes Warner Bros to walk away from Netflix deal, WSJ reports By Reuters - Investing.com
Activist Ancora builds $200 mln stake in Warner, opposes Netflix deal- WSJ - Investing.com
Netflix Denies 'The Wonderfools' May 15 Release - 조선일보
Activist Ancora builds $200 mln stake in Warner, opposes Netflix deal- WSJ By Investing.com - Investing.com South Africa
Paramount sweetens Warner Bros bid with offer to pay Netflix break-up cost, other fees - The Detroit News
Exclusive | Activist Investor Pushes Warner to Walk Away From Netflix Deal - The Wall Street Journal
Activist investor Ancora pushes Warner Bros to walk away from Netflix deal, WSJ reports - Reuters
PATENT—Fed. Cir.: $2.5 million jury... - VitalLaw.com
Here’s why Warner Bros. Discovery might have to take a closer look at Paramount’s ‘unsweet’ bid - Yahoo Finance
Stock-Split Watch: Is Nvidia (NVDA) Next? - The Motley Fool
‘Stranger Things: The First Shadow’ Broadway Play to Be Filmed for Netflix Release - IMDb
Paramount sweetens its bid for Warner Bros. Discovery with ‘additional benefits’ - Fast Company
Paramount raises offer for Warner as it seeks to fight off Netflix - Fortune
Paramount sweetens Warner Bros bid with extra cash, Netflix break-up fee cover - BNN Bloomberg
Netflix and Paramount’s billion-dollar Warner battle - Rolling Out
Netflix shares ‘One Piece’ season 2 official trailer - My Clallam County
Paramount has enhanced its offer for Warner Bros. Discovery with a $0.25 per share so called "ticking fee” payable to WBD shareholders and other measures. Read more below. - facebook.com
Paramount Skydance enhances Warner Bros acquisition offer to compete with Netflix - Yahoo! Finance Canada
David Ellison Adds New Sweeteners In Hostile Paramount Megadeal Bid For Warner Bros. - The Hollywood Reporter
Paramount, Netflix continue verbal and business battle over Wbd - IMDb
Warner Bros. Discovery Says Its Board Will Review Paramount’s Upgraded Hostile Takeover Offer - IMDb
‘Chicken Shop Date’ Creator Amelia Dimoldenberg to Star in and Produce Romantic Comedy About Celebrity Interviewer for Orion Pictures (Exclusive) - IMDb
Paramount Amends Warner Bid To Cover Netflix Breakup Fee - Law360
Paramount offers to pay $2.8 billion breakup fee in Warner deal - MSN
Warner Bros Discovery Inc: Board is not modifying its recommendation with respect to Netflix merger agreement - marketscreener.com
Eddie Vedder Changed Kids' Lives With Pearl Jam. Now, He and His Wife, Jill, Are Trying to Save Them - Rolling Stone
Paramount Puts Its Money Where Its Mouth Is With New Warner Bros. Offer - Investor's Business Daily
Netflix Inc (NFLX) Shares Up 3.14% on Feb 10 - GuruFocus
Factbox-By the numbers: How the Netflix, Paramount bids for Warner Bros stack up By Reuters - Investing.com
Netflix (NFLX) Sees Surge in Bullish Option Activity - GuruFocus
Paramount offers to pay US$2.8 bil breakup fee in Warner deal - The Edge Malaysia
Paramount sweetens hostile bid to stop Netflix-Warner Bros. deal - CNN
What to know about Netflix’s landmark acquisition of Warner Bros. - TechCrunch
Paramount Sweetens Warner Bros. Bid Terms to Woo Investors - Bloomberg.com
Paramount Sweetens Warner Bros Bid With Ticking Fee, Netflix Break-up Fee Cover - GV Wire
David Ellison kicks in a few billion more as he makes his 9th bid for Warner Bros. Discovery - Business Insider
Netflix and Oracle among market cap stock movers on Tuesday - Investing.com
Paramount Sweetens Hostile WBD Bid, Willing to Pay $2.8 Billion Termination Fee to Netflix, Among Other Considerations - Media Play News
Chief Financial Officer Of Netflix Sold $751K In Stock - Benzinga
Netflix Stock Tanks 39% — Is It Too Cheap to Ignore? - AOL.com
Paramount Skydance sweetens WBD offer as it vies to topple Netflix deal - Yahoo Finance
Paramount Sweetens Warner Bros. Discovery Bid, Offers to Pay $2.8 Billion Netflix Termination Fee - TheWrap
'Starlight' Netflix K-Drama Romantic Comedy Film Starring Kim Min Ah Begins Filming in February 2026 - What's on Netflix
Cinematographer Juanmi Azpiroz on Crafting the Look of Netflix’s ‘The Rip’ - What's on Netflix
Federal Circuit Voids $2.5M Netflix Patent Verdict, Finds Streaming Patents Invalid Under Alice - USA Herald
Netflix Inc Azioni (NFLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):